163 related articles for article (PubMed ID: 35713168)
1. Incidence and prognostic value of central nervous system involvement in infants with B-cell precursor acute lymphoblastic leukemia treated according to the MLL-Baby protocol.
Popov A; Tsaur G; Permikin Z; Fominikh V; Verzhbitskaya T; Riger T; Demina A; Shorikov E; Kustanovich A; Movchan L; Streneva O; Khlebnikova O; Makarova O; Arakaev O; Solodovnikov A; Boichenko E; Kondratchik K; Ponomareva N; Lapotentova E; Aleinikova O; Miakova N; Novichkova G; Karachunskiy A; Fechina L
Pediatr Blood Cancer; 2022 Sep; 69(9):e29860. PubMed ID: 35713168
[TBL] [Abstract][Full Text] [Related]
2. Genetic characteristics and treatment outcome in infants with KMT2A germline B-cell precursor acute lymphoblastic leukemia: Results of MLL-Baby protocol.
Popov A; Tsaur G; Permikin Z; Henze G; Verzhbitskaya T; Plekhanova O; Nokhrina E; Valochnik A; Sibiryakov P; Zerkalenkova E; Olshanskaya Y; Gindina T; Movchan L; Shorikov E; Streneva O; Khlebnikova O; Makarova O; Arakaev O; Boichenko E; Kondratchik K; Ponomareva N; Lapotentova E; Aleinikova O; Miakova N; Novichkova G; Karachunskiy A; Fechina L
Pediatr Blood Cancer; 2023 Apr; 70(4):e30204. PubMed ID: 36715125
[TBL] [Abstract][Full Text] [Related]
3. Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements.
Popov A; Tsaur G; Verzhbitskaya T; Riger T; Permikin Z; Demina A; Mikhailova E; Shorikov E; Arakaev O; Streneva O; Khlebnikova O; Makarova O; Miakova N; Fominikh V; Boichenko E; Kondratchik K; Ponomareva N; Novichkova G; Karachunskiy A; Fechina L
Br J Haematol; 2023 May; 201(3):510-519. PubMed ID: 34970734
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
Tsaur G; Popov A; Riger T; Kustanovich A; Solodovnikov A; Shorikov E; Demina A; Verzhbitskaya T; Streneva O; Makarova O; Lapotentova E; Aleinikova O; Miakova N; Boichenko E; Kondratchik K; Ponomareva N; Karachunskiy A; Roumiantsev A; Fechina L
Br J Haematol; 2021 Jun; 193(6):1151-1156. PubMed ID: 33583020
[TBL] [Abstract][Full Text] [Related]
5. Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements.
Wen J; Zhou M; Shen Y; Long Y; Guo Y; Song L; Xiao J
BMC Cancer; 2022 Aug; 22(1):859. PubMed ID: 35933338
[TBL] [Abstract][Full Text] [Related]
6. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study.
Kim R; Bergugnat H; Pastoret C; Pasquier F; Raffoux E; Larcher L; Passet M; Grardel N; Delabesse E; Kubetzko S; Caye-Eude A; Meyer C; Marschalek R; Lafage-Pochitaloff M; Thiebaut-Bertrand A; Balsat M; Escoffre-Barbe M; Blum S; Baumann M; Banos A; Straetmans N; Gallego-Hernanz MP; Chalandon Y; Graux C; Soulier J; Leguay T; Hunault M; Huguet F; Lhéritier V; Dombret H; Boissel N; Clappier E
Blood; 2023 Nov; 142(21):1806-1817. PubMed ID: 37595275
[TBL] [Abstract][Full Text] [Related]
7. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial.
Tomizawa D; Miyamura T; Imamura T; Watanabe T; Moriya Saito A; Ogawa A; Takahashi Y; Hirayama M; Taki T; Deguchi T; Hori T; Sanada M; Ohmori S; Haba M; Iguchi A; Arakawa Y; Koga Y; Manabe A; Horibe K; Ishii E; Koh K
Blood; 2020 Oct; 136(16):1813-1823. PubMed ID: 32845001
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol.
Stutterheim J; de Lorenzo P; van der Sluis IM; Alten J; Ancliffe P; Attarbaschi A; Aversa L; Boer JM; Biondi A; Brethon B; Diaz P; Cazzaniga G; Escherich G; Ferster A; Kotecha RS; Lausen B; Leung AW; Locatelli F; Silverman L; Stary J; Szczepanski T; van der Velden VHJ; Vora A; Zuna J; Schrappe M; Valsecchi MG; Pieters R
Eur J Cancer; 2022 Jan; 160():72-79. PubMed ID: 34785111
[TBL] [Abstract][Full Text] [Related]
9. Clinical Implications of Minimal Residual Disease Detection in Infants With
Stutterheim J; van der Sluis IM; de Lorenzo P; Alten J; Ancliffe P; Attarbaschi A; Brethon B; Biondi A; Campbell M; Cazzaniga G; Escherich G; Ferster A; Kotecha RS; Lausen B; Li CK; Lo Nigro L; Locatelli F; Marschalek R; Meyer C; Schrappe M; Stary J; Vora A; Zuna J; van der Velden VHJ; Szczepanski T; Valsecchi MG; Pieters R
J Clin Oncol; 2021 Feb; 39(6):652-662. PubMed ID: 33405950
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ;
Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia.
Yu CH; Jou ST; Su YH; Coustan-Smith E; Wu G; Cheng CN; Lu MY; Lin KH; Wu KH; Chen SH; Huang FL; Chang HH; Wang JL; Yen HJ; Li MJ; Chou SW; Ho WL; Liu YL; Chang CC; Lin ZS; Lin CY; Chen HY; Ni YL; Lin DT; Lin SW; Yang JJ; Ni YH; Pui CH; Yu SL; Yang YL
Cancer; 2023 Mar; 129(5):790-802. PubMed ID: 36537587
[TBL] [Abstract][Full Text] [Related]
12. A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurement.
Popov A; Henze G; Roumiantseva J; Budanov O; Belevtsev M; Verzhbitskaya T; Boyakova E; Movchan L; Tsaur G; Fadeeva M; Lagoyko S; Zharikova L; Miakova N; Litvinov D; Khlebnikova O; Streneva O; Stolyarova E; Ponomareva N; Novichkova G; Fechina L; Aleinikova O; Karachunskiy A
Pediatr Blood Cancer; 2023 Jun; 70(6):e30295. PubMed ID: 36975157
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
14. Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients.
Gao C; Zhao XX; Li WJ; Cui L; Zhao W; Liu SG; Yue ZX; Jiao Y; Wu MY; Li ZG
Am J Hematol; 2012 Nov; 87(11):1022-7. PubMed ID: 22911440
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease in cerebrospinal fluid at diagnosis: a more intensive treatment protocol was able to eliminate the adverse prognosis in children with acute lymphoblastic leukemia.
Biojone E; Queiróz Rde P; Valera ET; Odashima NS; Takayanagui OM; Viana MB; Tone LG; Scrideli CA
Leuk Lymphoma; 2012 Jan; 53(1):89-95. PubMed ID: 21774746
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene-rearranged acute lymphoblastic leukemia.
Takachi T; Watanabe T; Miyamura T; Moriya Saito A; Deguchi T; Hori T; Yamada T; Ohmori S; Haba M; Aoki Y; Ishimaru S; Sasaki S; Ohshima J; Iguchi A; Takahashi Y; Hyakuna N; Manabe A; Horibe K; Ishii E; Koh K; Tomizawa D
Blood Adv; 2021 Oct; 5(19):3891-3899. PubMed ID: 34500465
[TBL] [Abstract][Full Text] [Related]
17. Absolute count of leukemic blasts in cerebrospinal fluid as detected by flow cytometry is a relevant prognostic factor in children with acute lymphoblastic leukemia.
Popov A; Henze G; Verzhbitskaya T; Roumiantseva J; Lagoyko S; Khlebnikova O; Streneva O; Bidanov O; Tsaur G; Inaba H; Karachunskiy A; Fechina L
J Cancer Res Clin Oncol; 2019 May; 145(5):1331-1339. PubMed ID: 30840196
[TBL] [Abstract][Full Text] [Related]
18. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
Jiang H; Gu LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Xu C; Dong L; Zhou M
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450
[TBL] [Abstract][Full Text] [Related]
20. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
